HMG1 (high mobility group 1) is a ubiquitous and abundant chromatin component. However,
HMG1 can be secreted by activated macrophages and monocytes, and can act as a …

In the clinic, chimeric antigen receptor–modified T (CAR T) cell therapy is frequently associated
with life-threatening cytokine-release syndrome (CRS) and neurotoxicity. Understanding …

Insertional mutagenesis represents a major hurdle to gene therapy and necessitates
sensitive preclinical genotoxicity assays. Cdkn2a −/− mice are susceptible to a broad range of …

γ-Retroviral vectors (γRVs), which are commonly used in gene therapy, can trigger oncogenesis
by insertional mutagenesis. Here, we have dissected the contribution of vector design …

Sterol metabolism has recently been linked to innate and adaptive immune responses
through liver X receptor (LXR) signaling. Whether products of sterol metabolism interfere with …

Chimeric antigen receptor (CAR) T cell expansion and persistence represent key factors to
achieve complete responses and prevent relapses. These features are typical of early …

High mobility group box 1 protein (HMGB1) is a chromatin component leaked out by necrotic
cells and actively secreted by activated myeloid cells. The extracellular protein is a potent …

By immunofluorescence on cytospin preparations and on semithin sections of mouse
pancreatic buds, we have found glucagon and pancreatic polypeptide (PP)-containing cells at …

Type I mucopolysaccharidosis (MPS I) is a lysosomal storage disorder caused by the deficiency
of α-L-iduronidase, which results in glycosaminoglycan accumulation in tissues. Clinical …

Targeted genome editing in hematopoietic stem/progenitor cells (HSPCs) is an attractive
strategy for treating immunohematological diseases. However, the limited efficiency of …